封面
市場調查報告書
商品編碼
1728094

冷凍乾燥注射劑市場-全球產業規模、佔有率、趨勢、機會和預測(按包裝、按交付、按適應症、按最終用戶、按地區和競爭細分,2020-2030 年)

Lyophilized Injectable Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Packaging, By Delivery, By Indication, By End-User, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球冷凍乾燥注射劑市值為 31.4 億美元,預計到 2030 年將達到 54.1 億美元,預測期內複合年成長率為 9.49%。冷凍乾燥注射劑,也稱為冷凍乾燥注射劑,是經過冷凍乾燥過程以提高產品穩定性、保存期限和運輸便利性的關鍵藥物製劑。該技術包括冷凍注射溶液,然後透過昇華去除水分,從而形成固體乾燥形式,可以在注射前輕鬆重建。此方法對於生物製劑、疫苗和其他溫度敏感化合物特別有價值。不斷增加的研發活動、製藥巨頭和合約製造組織之間的全球合作以及對長效和穩定藥物製劑的需求不斷成長正在推動市場成長。值得注意的是,產業參與者正在擴大研發能力,例如輝瑞在印度的開發中心,該中心專注於 API 和成品劑型,包括冷凍乾燥產品。隨著生物製劑和個人化治療的持續發展,預計冷凍乾燥注射劑在整個醫療保健生態系統中的應用將加速。

市場概覽
預測期 2026-2030
2024年市場規模 31.4億美元
2030年市場規模 54.1億美元
2025-2030 年複合年成長率 9.49%
成長最快的領域 一次使用小瓶
最大的市場 北美洲

關鍵市場促進因素

生物製劑和特種藥物的需求不斷成長

主要市場挑戰

開發和製造成本高

主要市場趨勢

生物製劑和生物相似藥的擴張

目錄

第 1 章:產品概述

第2章:研究方法

第3章:執行摘要

第4章:顧客之聲

第5章:全球凍乾注射劑市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按包裝(一次性小瓶、即時復溶、特殊包裝)
    • 透過遞送(預充式稀釋劑注射器、專有重構裝置、單步驟裝置、多步驟裝置)
    • 按適應症(自體免疫疾病、傳染病、代謝性疾病、其他)
    • 按最終用戶(醫院藥房、零售藥房、其他)
    • 按地區
    • 按公司分類(2024)
  • 市場地圖

第6章:北美冷凍乾燥注射劑市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美:國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章:歐洲凍乾注射劑市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲:國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第8章:亞太地區冷凍乾燥注射劑市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區:國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章:南美洲凍乾注射劑市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲:國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章:中東和非洲冷凍乾燥注射劑市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA:國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章:市場動態

  • 驅動程式
  • 挑戰

第 12 章:市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章:全球冷凍乾燥注射劑市場:SWOT 分析

第 14 章:競爭格局

  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Schott AG
  • Aristopharma Ltd.
  • Vetter Pharma GmbH
  • Jubilant HollisterStier LLC
  • Bristol Myers Squibb
  • F. Hoffmann-La Roche Ltd
  • Novo Nordisk A/S

第 15 章:策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 16994

The Global Lyophilized Injectable Market was valued at USD 3.14 billion in 2024 and is projected to reach USD 5.41 billion by 2030, growing at a CAGR of 9.49% during the forecast period. Lyophilized injectables, also known as freeze-dried injectables, are critical pharmaceutical formulations that undergo a lyophilization process to enhance product stability, shelf life, and ease of transport. This technique involves freezing the injectable solution and then removing moisture through sublimation, resulting in a solid, dry form that can be easily reconstituted before administration. The method is particularly valuable for biologics, vaccines, and other temperature-sensitive compounds. Increasing R&D activities, global collaborations between pharmaceutical giants and contract manufacturing organizations, and the rising demand for long-acting and stable drug formulations are driving market growth. Notably, industry players are expanding R&D capabilities, as seen in initiatives like Pfizer's development hub in India, which focuses on APIs and finished dosage forms, including lyophilized products. As biologics and personalized therapies continue to gain momentum, the adoption of lyophilized injectables is expected to accelerate across the healthcare ecosystem.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 3.14 Billion
Market Size 2030USD 5.41 Billion
CAGR 2025-20309.49%
Fastest Growing SegmentSingle-Use Vials
Largest MarketNorth America

Key Market Drivers

Increasing Demand for Biologics and Specialty Drugs

The rising demand for biologics and specialty medications is a major factor boosting the growth of the lyophilized injectable market. Biologics have gained prominence due to their targeted effectiveness in treating chronic and complex conditions such as cancer, autoimmune diseases, and rare disorders. Unlike conventional small molecule drugs, biologics require specific storage and delivery conditions, making lyophilization an ideal method for maintaining their structural and therapeutic integrity. As pharmaceutical firms expand their biologics portfolios, lyophilized formulations are increasingly preferred to ensure long-term stability and patient safety. The demand for individualized treatment approaches, coupled with the need for advanced drug delivery systems, continues to push lyophilized technologies into the spotlight. Healthcare providers are also prioritizing injectables that combine extended shelf life with minimal preparation time, reinforcing the need for robust and reliable freeze-dried drug formats.

Key Market Challenges

High Development and Manufacturing Costs

One of the major challenges impeding market expansion is the high cost associated with developing and manufacturing lyophilized injectable products. The lyophilization process involves sophisticated technology, including specialized equipment and rigorous validation protocols, all of which demand significant capital investment. Moreover, maintaining stringent quality control and regulatory compliance adds to the financial burden. These elevated production expenses often translate into higher product prices, potentially limiting access to such therapies in price-sensitive markets. Additionally, small- and mid-sized pharmaceutical firms may hesitate to invest in lyophilized drug development due to the associated operational and financial risks, which can slow the pace of innovation and new product introductions.

Key Market Trends

Expansion of Biologics and Biosimilars

A key trend shaping the lyophilized injectable market is the rapid expansion of biologics and biosimilars. Biologic therapies-including monoclonal antibodies, therapeutic proteins, and vaccines-often require lyophilization to maintain efficacy throughout their lifecycle. As global demand for these therapies grows, pharmaceutical manufacturers are increasingly focused on enhancing lyophilization processes to meet regulatory standards and market expectations. Biosimilars, which offer cost-effective alternatives to branded biologics, are also contributing to the demand for freeze-dried injectable formulations. This trend is stimulating innovation in lyophilization equipment, packaging, and formulation techniques, resulting in greater product availability, improved patient compliance, and increased competitiveness across global markets.

Key Market Players

  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Schott AG
  • Aristopharma Ltd.
  • Vetter Pharma GmbH
  • Jubilant HollisterStier LLC
  • Bristol Myers Squibb
  • F. Hoffmann-La Roche Ltd
  • Novo Nordisk A/S

Report Scope:

In this report, the Global Lyophilized Injectable Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lyophilized Injectable Market, By Packaging:

  • Single-Use Vials
  • Point-Of-Care Reconstitution
  • Specialty Packaging

Lyophilized Injectable Market, By Delivery:

  • Prefilled Diluent Syringes
  • Proprietary Reconstitution Devices
  • Single-Step Devices
  • Multi-Step Devices

Lyophilized Injectable Market, By Indication:

  • Autoimmune Diseases
  • Infectious Diseases
  • Metabolic Conditions
  • Others

Lyophilized Injectable Market, By End-User:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Lyophilized Injectable Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lyophilized Injectable Market.

Available Customizations:

Global Lyophilized Injectable Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Indications
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lyophilized Injectable Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Packaging (Single-Use Vials, Point-Of-Care Reconstitution, Specialty Packaging)
    • 5.2.2. By Delivery (Prefilled Diluent Syringes, Proprietary Reconstitution Devices, Single-Step Devices, Multi-Step Devices)
    • 5.2.3. By Indication (Autoimmune Diseases, Infectious Diseases, Metabolic Conditions, Others)
    • 5.2.4. By End-User (Hospital Pharmacy, Retail Pharmacy, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Lyophilized Injectable Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Packaging
    • 6.2.2. By Delivery
    • 6.2.3. By Indication
    • 6.2.4. By End-User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Lyophilized Injectable Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Packaging
        • 6.3.1.2.2. By Delivery
        • 6.3.1.2.3. By Indication
        • 6.3.1.2.4. By End-User
    • 6.3.2. Canada Lyophilized Injectable Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Packaging
        • 6.3.2.2.2. By Delivery
        • 6.3.2.2.3. By Indication
        • 6.3.2.2.4. By End-User
    • 6.3.3. Mexico Lyophilized Injectable Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Packaging
        • 6.3.3.2.2. By Delivery
        • 6.3.3.2.3. By Indication
        • 6.3.3.2.4. By End-User

7. Europe Lyophilized Injectable Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Packaging
    • 7.2.2. By Delivery
    • 7.2.3. By Indication
    • 7.2.4. By End-User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Lyophilized Injectable Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Packaging
        • 7.3.1.2.2. By Delivery
        • 7.3.1.2.3. By Indication
        • 7.3.1.2.4. By End-User
    • 7.3.2. United Kingdom Lyophilized Injectable Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Packaging
        • 7.3.2.2.2. By Delivery
        • 7.3.2.2.3. By Indication
        • 7.3.2.2.4. By End-User
    • 7.3.3. Italy Lyophilized Injectable Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Packaging
        • 7.3.3.2.2. By Delivery
        • 7.3.3.2.3. By Indication
        • 7.3.3.2.4. By End-User
    • 7.3.4. France Lyophilized Injectable Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Packaging
        • 7.3.4.2.2. By Delivery
        • 7.3.4.2.3. By Indication
        • 7.3.4.2.4. By End-User
    • 7.3.5. Spain Lyophilized Injectable Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Packaging
        • 7.3.5.2.2. By Delivery
        • 7.3.5.2.3. By Indication
        • 7.3.5.2.4. By End-User

8. Asia-Pacific Lyophilized Injectable Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Packaging
    • 8.2.2. By Delivery
    • 8.2.3. By Indication
    • 8.2.4. By End-User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Lyophilized Injectable Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Packaging
        • 8.3.1.2.2. By Delivery
        • 8.3.1.2.3. By Indication
        • 8.3.1.2.4. By End-User
    • 8.3.2. India Lyophilized Injectable Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Packaging
        • 8.3.2.2.2. By Delivery
        • 8.3.2.2.3. By Indication
        • 8.3.2.2.4. By End-User
    • 8.3.3. Japan Lyophilized Injectable Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Packaging
        • 8.3.3.2.2. By Delivery
        • 8.3.3.2.3. By Indication
        • 8.3.3.2.4. By End-User
    • 8.3.4. South Korea Lyophilized Injectable Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Packaging
        • 8.3.4.2.2. By Delivery
        • 8.3.4.2.3. By Indication
        • 8.3.4.2.4. By End-User
    • 8.3.5. Australia Lyophilized Injectable Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Packaging
        • 8.3.5.2.2. By Delivery
        • 8.3.5.2.3. By Indication
        • 8.3.5.2.4. By End-User

9. South America Lyophilized Injectable Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Packaging
    • 9.2.2. By Delivery
    • 9.2.3. By Indication
    • 9.2.4. By End-User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Lyophilized Injectable Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Packaging
        • 9.3.1.2.2. By Delivery
        • 9.3.1.2.3. By Indication
        • 9.3.1.2.4. By End-User
    • 9.3.2. Argentina Lyophilized Injectable Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Packaging
        • 9.3.2.2.2. By Delivery
        • 9.3.2.2.3. By Indication
        • 9.3.2.2.4. By End-User
    • 9.3.3. Colombia Lyophilized Injectable Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Packaging
        • 9.3.3.2.2. By Delivery
        • 9.3.3.2.3. By Indication
        • 9.3.3.2.4. By End-User

10. Middle East and Africa Lyophilized Injectable Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Packaging
    • 10.2.2. By Delivery
    • 10.2.3. By Indication
    • 10.2.4. By End-User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Lyophilized Injectable Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Packaging
        • 10.3.1.2.2. By Delivery
        • 10.3.1.2.3. By Indication
        • 10.3.1.2.4. By End-User
    • 10.3.2. Saudi Arabia Lyophilized Injectable Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Packaging
        • 10.3.2.2.2. By Delivery
        • 10.3.2.2.3. By Indication
        • 10.3.2.2.4. By End-User
    • 10.3.3. UAE Lyophilized Injectable Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Packaging
        • 10.3.3.2.2. By Delivery
        • 10.3.3.2.3. By Indication
        • 10.3.3.2.4. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Lyophilized Injectable Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. B. Braun Melsungen AG
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Baxter International Inc.
  • 14.3. Becton, Dickinson and Company
  • 14.4. Schott AG
  • 14.5. Aristopharma Ltd.
  • 14.6. Vetter Pharma GmbH
  • 14.7. Jubilant HollisterStier LLC
  • 14.8. Bristol Myers Squibb
  • 14.9. F. Hoffmann-La Roche Ltd
  • 14.10. Novo Nordisk A/S

15. Strategic Recommendations

16. About Us & Disclaimer